Drug combinations in diabetic neuropathic pain: an experimental validation

Primary tabs

SCIENCE
Drug combinations in diabetic neuropathic pain: an experimental validation
Key Take-Away: 

The nerve disorder arising due to diabetes is known as diabetic neuropathy. Duloxetine, sitagliptin, pregabalin and amitriptyline and the combinations of these drugs to relieve from the diabetic neuropathic pain have been well explained in this study.

Diabetic neuropathy is the most common complication of diabetes mellitus, and the different drug combinations available do not provide effective pain relief. 

ABSTRACT: 
Background: 

Diabetic neuropathy is the most common complication of diabetes mellitus, and the different drug combinations available do not provide effective pain relief.

The present study was performed to observe the effect of amitriptyline, duloxetine, sitagliptin, and pregabalin, and their combinations on streptozotocin (STZ)-induced diabetic neuropathy.

Methods: 

Diabetic neuropathy was induced by STZ, and the tail-flick test was used to assess thermal hyperalgesia before and after (at 30, 60, and 120 min) drug administration.

One week after STZ administration, the blood glucose level was observed to be in the diabetic range.

Results: 

Administration of all the drugs except sitagliptin increased the tail-flick latency significantly as compared to control. Further, the drugs amitriptyline, duloxetine, and pregabalin showed significant pain-relieving effect, when either two of them were administered in combination, although the different combinations had varied degree of pain relief.

However, sitagliptin was observed to have no effect when administered alone or in combination with the other three drugs.

 

Conclusion: 

Therefore, the study provides new insights concerning combined therapy of pain, which further needs clinical exploration.

J Basic Clin Physiol Pharmacol. 2016 Jun 22
Log in or register to post comments